LEP and amyotrophic lateral sclerosis: The biological impact of leptin treatment during the progression of ALS is unknown, even though this hormone has previously been shown to be associated with a lower risk of ALS disease and to confer a survival advantage in ALS patients (Nagel et al., 2017; Ngo et al., 2015).